Royal Bank Of Canada Autolus Therapeutics PLC Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$5.39 - $7.29 $91 - $123	17 New	17 $0
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $2 - $3	1 Added 6.25%	17 $0
Q2 2023 Aug 14, 2023	SELL	$1.64 - $3.21 $32,793 - $64,187	-19,996 Reduced 99.92%	16 $0
Q1 2023 May 15, 2023	BUY	$1.75 - $2.25 $34,923 - $44,901	19,956 Added 35635.71%	20,012 $36,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $20 - $39	12 Added 27.27%	56 $0
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $7 - $10	2 Added 4.76%	44 $0
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $499 - $686	-98 Reduced 70.0%	42 $0
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $425 - $589	80 Added 133.33%	140 $1,000
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $286 - $477	60 New	60 $0

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.